Trial · NCT06922591
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase 1: Maximum Tolerated Dose | 21 days | To determine the MTD and RD(s) of TNG462 in combination with RMC-6236 or RMC-9805 |
| Primary | Phase 1: Maximum Tolerated Dose | 28 days | To determine the MTD and RD(s) of TNG462 in combination with mFOLFIRINOX or gemcitabine/nab-paclitaxel |
| Primary | Phase 2: Combination Anti-neoplastic Activity | 12 weeks | To assess preliminary evidence of antineoplastic activity of TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel using RECIST 1.1 |
| Secondary | Phase 1: Combination Anti-neoplastic Activity | 12 weeks | To assess preliminary evidence of antineoplastic activity of TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX, or gemcitabine/nab paclitaxel using RECIST 1.1 |
| Secondary | Phase 1 and 2: Tmax of TNG462 and in Combination | 21 days | To characterize the Tmax of TNG462 in combination with RMC-6236 or RMC-9805 |
| Secondary | Phase 1 and 2: Tmax of TNG462 and in Combination | 28 days | To characterize the Tmax of TNG462 in combination with mFOLFIRINOX, or gemcitabine/nab-paclitaxel |
| Secondary | Phase 1 and 2: Cmax of TNG462 and in Combination | 21 days | To characterize the Cmax of TNG462 in combination with RMC-6236 or RMC-9805 |
| Secondary | Phase 1 and 2: Cmax of TNG462 and in Combination | 28 days | To characterize the Cmax of TNG462 in combination with mFOLFIRINOX, or gemcitabine/nab-paclitaxel |
| Secondary | Phase 1 and 2: AUC of TNG462 and in Combination | 21 days | To characterize the AUC of TNG462 and in combination with RMC-6236 or RMC-9805 |
| Secondary | Phase 1 and 2: AUC of TNG462 and in Combination | 28 days | To characterize the AUC of TNG462 in combination with mFOLFIRINOX, or gemcitabine/nab-paclitaxel |
| Secondary | Phase 1 and 2 Adverse Event Profile | 21 days | To determine the safety and tolerability of TNG462 in combination with RMC-6236 or RMC-9805 |
| Secondary | Phase 1 and 2 Adverse Event Profile | 28 days | To determine the safety and tolerability of TNG462 in combination with mFOLFIRINOX or gemcitabine nab-paclitaxel |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06922591/registered